Hutchmed China Limited Adr (HCM)

May 22, 2026

HUTCHMED (Nasdaq: HCM) showcases savolitinib, fruquintinib and surufatinib data at ASCO 2026 - Stock Titan

May 22, 2026

May 21, 2026

HUTCHMED: ELUNATE and TYVYT Combination Therapy Approved by NMPA for Advanced or Metastatic Renal Cell Carcinoma - AASTOCKS.com

May 21, 2026

May 21, 2026

HUTCHMED to Present Multiple Study Data at ASCO Annual Meeting in US - AASTOCKS.com

May 21, 2026

May 21, 2026

New HUTCHMED (HCM) ELUNATE plus TYVYT approval targets second-line kidney cancer - Stock Titan

May 21, 2026

May 12, 2026

HUTCHMED (HCM) shareholders back all AGM votes including 2026 option scheme - Stock Titan

May 12, 2026

May 01, 2026

HUTCHMED (NASDAQ:HCM) Hits New 52-Week LowWhat's Next? - MarketBeat

May 01, 2026

May 01, 2026

HUTCHMED To Present Data at American Association of Cancer Research Annual Meeting 2026 - AASTOCKS.com

May 01, 2026

Apr 30, 2026

HUTCHMED (Nasdaq: HCM) reports 872,335,120 voting shares - Stock Titan

Apr 30, 2026

Apr 29, 2026

和黃醫藥(00013.HK)索樂匹尼布上市申請獲受理並納入優先審評 - AASTOCKS.com

Apr 29, 2026

Apr 29, 2026

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times

Apr 29, 2026

Apr 29, 2026

HUTCHMED (Nasdaq: HCM) gains China priority review and breakthrough status for sovleplenib - Stock Titan

Apr 29, 2026

Apr 28, 2026

HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference - Yahoo Finance

Apr 28, 2026

Apr 24, 2026

HUTCHMED (NASDAQ:HCM) Shares Gap DownHere's Why - MarketBeat

Apr 24, 2026

Apr 23, 2026

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026 - The Manila Times

Apr 23, 2026

Apr 21, 2026

Hutchmed China (NASDAQ:HCM) Gains Attention Amid Healthcare Momentum - Kalkine Media

Apr 21, 2026

Apr 21, 2026

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Rating of "Hold" by Analysts - MarketBeat

Apr 21, 2026

Apr 15, 2026

Revenue per share of HUTCHMED (China) Limited Sponsored ADR – FWB:H7T1 - TradingView — Track All Markets

Apr 15, 2026

Apr 14, 2026

HCM Stock Price, Quote & Chart | HUTCHMED CHINA-ADR (NASDAQ:HCM) - ChartMill

Apr 14, 2026

Apr 09, 2026

HUTCHMED (HCM) showcases ATTC and surufatinib study data at AACR 2026 - Stock Titan

Apr 09, 2026

Apr 09, 2026

HUTCHMED (HCM) plans 2026 AGM, 10% buyback mandate and 5% option pool - Stock Titan

Apr 09, 2026

Apr 08, 2026

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 - GlobeNewswire

Apr 08, 2026

Apr 08, 2026

HUTCHMED (LON:HCM) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World

Apr 08, 2026

Apr 05, 2026

Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - Yahoo Finance Singapore

Apr 05, 2026

Apr 04, 2026

Zai Lab Limited (ZLAB) stock price, news, quote and history - uk.finance.yahoo.com

Apr 04, 2026

Apr 03, 2026

Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo Finance

Apr 03, 2026

Mar 31, 2026

Short Interest in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Decreases By 13.7% - MarketBeat

Mar 31, 2026

Mar 30, 2026

HUTCHMED (NASDAQ:HCM) Shares Gap UpTime to Buy? - MarketBeat

Mar 30, 2026

Mar 27, 2026

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat

Mar 27, 2026

Mar 26, 2026

HUTCHMED (NASDAQ:HCM) Stock Price Crosses Below 50-Day Moving AverageHere's Why - MarketBeat

Mar 26, 2026

Mar 23, 2026

HUTCHMED (Nasdaq: HCM) launches registrational Phase III HMPL-760 lymphoma trial in China - Stock Titan

Mar 23, 2026

Mar 22, 2026

HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China - GlobeNewswire Inc.

Mar 22, 2026

Mar 16, 2026

HUTCHMED (HCM) vests 19,913 LTIP shares for CEO Dr. Weiguo Su - Stock Titan

Mar 16, 2026

Mar 12, 2026

HUTCHMED (China) Limited Sponsored ADR $HCM Stake Trimmed by Schroder Investment Management Group - MarketBeat

Mar 12, 2026

Mar 12, 2026

HUTCHMED (LON:HCM) Share Price Crosses Below 200-Day Moving Average – Time to Sell? - Defense World

Mar 12, 2026

Mar 11, 2026

HUTCHMED (HCM) vests 726,317 LTIP shares to CEO and CFO - Stock Titan

Mar 11, 2026

Mar 09, 2026

TAZVERIK cancer drug withdrawn; HUTCHMED (HCM) ends China trials - Stock Titan

Mar 09, 2026

Mar 09, 2026

HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China - ChartMill

Mar 09, 2026

Mar 09, 2026

CLSA Cuts TP of HUTCHMED (00013.HK) to HKD30.4; Rating Outperform - AASTOCKS.com

Mar 09, 2026

Mar 06, 2026

Intended Retirement of Independent Non-executive Director and changes of composition of board committees - ChartMill

Mar 06, 2026

Mar 06, 2026

HUTCHMED (NASDAQ: HCM) plans INED retirement, reshapes board roles - Stock Titan

Mar 06, 2026

Mar 05, 2026

HUTCHMED H2 Earnings Call Highlights - Yahoo Finance

Mar 05, 2026

Mar 05, 2026

Food & Life Companies (3563.JP) Plunges 14% Following Alleged Parasite Egg Discovery at Beijing's Sushiro - AASTOCKS.com

Mar 05, 2026

Mar 05, 2026

[6-K] HUTCHMED (China) Ltd Current Report (Foreign Issuer) | HCM SEC FilingForm 6-K - Stock Titan

Mar 05, 2026

Mar 05, 2026

HUTCHMED Reports 2025 Full Year Results and Business Updates - GlobeNewswire

Mar 05, 2026

Mar 05, 2026

HUTCHMED (LON:HCM) Share Price Crosses Below 200-Day Moving Average – What’s Next? - Defense World

Mar 05, 2026

Mar 05, 2026

Brokerages Set QCR Holdings, Inc. (NASDAQ:QCRH) PT at $102.25 - Defense World

Mar 05, 2026

Mar 04, 2026

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors - GlobeNewswire

Mar 04, 2026

Mar 02, 2026

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Analysts - MarketBeat

Mar 02, 2026